Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (789) 789
Publication (18) 18
Book Review (10) 10
Magazine Article (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
probucol - therapeutic use (603) 603
humans (544) 544
male (403) 403
probucol (335) 335
animals (288) 288
female (279) 279
middle aged (226) 226
anticholesteremic agents - therapeutic use (191) 191
probucol - pharmacology (162) 162
cholesterol - blood (160) 160
adult (159) 159
antioxidants - therapeutic use (151) 151
hypercholesterolemia - drug therapy (137) 137
aged (130) 130
atherosclerosis (128) 128
index medicus (124) 124
phenols - therapeutic use (124) 124
rats (112) 112
antioxidants (105) 105
pharmacology & pharmacy (105) 105
triglycerides - blood (96) 96
cardiac & cardiovascular systems (91) 91
hyperlipidemias - drug therapy (82) 82
mice (82) 82
rabbits (79) 79
oxidative stress (77) 77
clinical trials as topic (76) 76
low-density-lipoprotein (76) 76
hyperlipoproteinemia type ii - drug therapy (75) 75
cholesterol (71) 71
drug therapy, combination (71) 71
lipids - blood (70) 70
peripheral vascular disease (70) 70
cholesterol, hdl - blood (65) 65
probucol - administration & dosage (65) 65
antioxidants - pharmacology (63) 63
lipoproteins, ldl - blood (62) 62
cholestyramine resin - therapeutic use (60) 60
hypolipidemic agents - therapeutic use (60) 60
time factors (60) 60
lipoproteins - blood (59) 59
arteriosclerosis - drug therapy (58) 58
cholesterol, ldl - blood (55) 55
probucol - adverse effects (53) 53
treatment outcome (53) 53
hypercholesterolemia (51) 51
arteriosclerosis - prevention & control (50) 50
hypercholesterolemia - blood (50) 50
disease models, animal (47) 47
probucol - analogs & derivatives (47) 47
anticholesteremic agents - pharmacology (46) 46
familial hypercholesterolemia (43) 43
heritable hyperlipidemic rabbit (43) 43
coronary disease - prevention & control (42) 42
hyperlipoproteinemia type ii - blood (41) 41
lipoproteins, ldl - metabolism (41) 41
arteriosclerosis - etiology (40) 40
antioxidant (39) 39
biochemistry & molecular biology (39) 39
clofibrate - therapeutic use (39) 39
double-blind method (38) 38
lipids (38) 38
niacin - therapeutic use (38) 38
progression (38) 38
arteriosclerosis - pathology (36) 36
endocrinology & metabolism (36) 36
inflammation (36) 36
lipid peroxidation - drug effects (36) 36
rats, sprague-dawley (36) 36
restenosis (36) 36
lipoproteins, hdl - blood (35) 35
oxidative stress - drug effects (35) 35
colestipol - therapeutic use (33) 33
follow-up studies (33) 33
lovastatin - therapeutic use (33) 33
prospective studies (33) 33
vitamin e - therapeutic use (33) 33
medicine, research & experimental (32) 32
oxidation-reduction (31) 31
vitamin-e (31) 31
cholesterol - metabolism (30) 30
prevention (30) 30
risk factors (30) 30
drug therapy (29) 29
hyperlipidemias - blood (29) 29
medicine, general & internal (29) 29
expression (28) 28
lipoproteins (28) 28
lipid peroxidation (27) 27
lipid-peroxidation (27) 27
diet (26) 26
phenols - pharmacology (26) 26
hydroxymethylglutaryl-coa reductase inhibitors (25) 25
hypercholesterolemia - complications (25) 25
apolipoproteins - blood (24) 24
apoptosis (24) 24
diabetes (24) 24
disease (24) 24
metabolism (24) 24
pravastatin - therapeutic use (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (681) 681
Japanese (28) 28
Russian (19) 19
French (14) 14
Portuguese (13) 13
Chinese (11) 11
Spanish (7) 7
Polish (6) 6
German (4) 4
Italian (4) 4
Bulgarian (2) 2
Czech (2) 2
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation
by Calleja, Miguel Angel and Vieites, Jose María and Montero-Meterdez, Trinidad and Torres, María Isabel and Faus, María José and Gil, Angel and Suárez, Antonio
British Journal of Nutrition, ISSN 0007-1145, 02/2013, Volume 109, Issue 3, pp. 394 - 401
Plant-based whole foods provide thousands of bioactive metabolites to the human diet that reduce the risk of developing chronic diseases. beta-Caryophyllene... 
β-Caryophyllene | Antioxidants | Hepatic stellate cells | Liver fibrosis | APOPTOSIS | ACID | ROSMARINUS-TOMENTOSUS | MECHANISM | COMPONENTS | SESQUITERPENE | PROLIFERATION | PEROXIDATION | THIOACETAMIDE | NUTRITION & DIETETICS | beta-Caryophyllene | EXPRESSION | Liver - pathology | Sesquiterpenes - metabolism | Rats, Wistar | Antioxidants - metabolism | Probucol - therapeutic use | Hepatic Stellate Cells - metabolism | Sesquiterpenes - administration & dosage | Carbon Tetrachloride Poisoning - prevention & control | Sesquiterpenes - therapeutic use | Probucol - pharmacology | Carbon Tetrachloride Poisoning - metabolism | Liver - drug effects | Arachidonate 5-Lipoxygenase - chemistry | Lipid Peroxidation - drug effects | Female | Flavoring Agents - therapeutic use | Free Radical Scavengers - therapeutic use | alpha-Tocopherol - metabolism | Hepatic Stellate Cells - drug effects | Cell Line | Cell Survival - drug effects | Arachidonate 5-Lipoxygenase - metabolism | Free Radical Scavengers - metabolism | Liver - metabolism | Hepatic Stellate Cells - enzymology | Free Radical Scavengers - administration & dosage | Lipoxygenase Inhibitors - therapeutic use | Rats | Flavoring Agents - metabolism | Antioxidants - pharmacology | Random Allocation | Flavoring Agents - administration & dosage | Carbon Tetrachloride Poisoning - pathology | Lipoxygenase Inhibitors - administration & dosage | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Animals | Antioxidants - administration & dosage | Lipoxygenase Inhibitors - metabolism | Oxidative Stress - drug effects | Dietary Supplements
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review
by Socha, Piotr and Horvath, Andrea and Vajro, Pietro and Dziechciarz, Piotr and Dhawan, Anil and Szajewska, Hania
Journal of Pediatric Gastroenterology and Nutrition, ISSN 0277-2116, 05/2009, Volume 48, Issue 5, pp. 587 - 596
BACKGROUND:Uncertainty exists regarding the treatment of patients with nonalcoholic fatty liver disease (NAFLD) who are unable to lose weight and/or change... 
NASH | NAFLD | Liver disease | VITAMIN-E TREATMENT | METFORMIN | WEIGHT-REDUCTION | EFFICACY | ABNORMALITIES | OBESE CHILDREN | NUTRITION & DIETETICS | URSODEOXYCHOLIC ACID | DOUBLE-BLIND | STEATOHEPATITIS NASH | PEDIATRICS | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | Hypoglycemic Agents - therapeutic use | Fatty Liver - diet therapy | Liver - pathology | Metformin - therapeutic use | Fatty Liver - pathology | Aspartate Aminotransferases - analysis | Humans | Probucol - therapeutic use | Alanine Transaminase - analysis | Fatty Liver - drug therapy | Randomized Controlled Trials as Topic | Ursodeoxycholic Acid - therapeutic use | Drug Synergism | Thiazolidinediones - therapeutic use | Carnitine - therapeutic use | Vitamin E - therapeutic use | Adult | Acetylcysteine - therapeutic use | Drug Therapy, Combination | Child | Dietary Supplements | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pharmacological inhibition of coronary restenosis: systemic and local approaches
by Guerra, Elena and Byrne, Robert A and Kastrati, Adnan
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 10/2014, Volume 15, Issue 15, pp. 2155 - 2171
Introduction: Percutaneous coronary intervention (PCI) with stent implantation has revolutionized the treatment of obstructive coronary artery disease.... 
oral sirolimus | stent | tranilast | restenosis | cilostazol | drug eluting balloon | probucol | Restenosis | Tranilast | Oral sirolimus | Cilostazol | Probucol | Drug eluting balloon | Stent | PROLIFERATOR-ACTIVATED RECEPTORS | TRIPLE ANTIPLATELET THERAPY | DRUG-ELUTING STENT | RANDOMIZED CONTROLLED-TRIAL | NEOINTIMAL TISSUE PROLIFERATION | PHARMACOLOGY & PHARMACY | PACLITAXEL-COATED BALLOON | PLACEBO-CONTROLLED TRIAL | BARE-METAL STENT | TYPE-2 DIABETES-MELLITUS | SERIAL INTRAVASCULAR ULTRASOUND | Vasodilator Agents - therapeutic use | Humans | ortho-Aminobenzoates - therapeutic use | Probucol - therapeutic use | Drug Delivery Systems | Drug-Eluting Stents - adverse effects | Anti-Bacterial Agents - therapeutic use | Tetrazoles - administration & dosage | Anti-Bacterial Agents - chemistry | Platelet Aggregation Inhibitors - administration & dosage | Tubulin Modulators - administration & dosage | Paclitaxel - administration & dosage | Platelet Aggregation Inhibitors - therapeutic use | Coronary Restenosis - etiology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | ortho-Aminobenzoates - administration & dosage | Coronary Restenosis - prevention & control | Paclitaxel - therapeutic use | Probucol - administration & dosage | Tubulin Modulators - therapeutic use | Sirolimus - administration & dosage | Antioxidants - therapeutic use | Antioxidants - administration & dosage | Tetrazoles - therapeutic use | Coronary Restenosis - physiopathology | Anti-Bacterial Agents - administration & dosage | Percutaneous Coronary Intervention - adverse effects | Vasodilator Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Where are we with probucol: A new life for an old drug?
by Yamashita, Shizuya and Matsuzawa, Yuji
Atherosclerosis, ISSN 0021-9150, 2009, Volume 207, Issue 1, pp. 16 - 23
Abstract Probucol has a long history of clinical application with established efficacy and safety profiles. Probucol is a potent anti-oxidant drug that has... 
Cardiovascular | Anti-oxidant | Atherosclerosis | Risk factor | HDL-cholesterol | Probucol | Familial hypercholesterolemia | Coronary artery disease | Cholesteryl ester transfer protein | CETP | ATHEROGENESIS | CHOLESTERYL ESTER TRANSFER | DEFICIENT MICE | TRIAL | RABBITS | RESTENOSIS | PERIPHERAL VASCULAR DISEASE | CORONARY ANGIOPLASTY | Cardiovascular Diseases - drug therapy | Humans | Probucol - therapeutic use | Probucol - adverse effects | Cardiovascular Diseases - genetics | Antioxidants - history | Anticholesteremic Agents - history | Cardiovascular Agents - history | Hyperlipoproteinemia Type II - drug therapy | Cardiovascular Diseases - metabolism | Risk Assessment | History, 20th Century | Treatment Outcome | Evidence-Based Medicine | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Hyperlipoproteinemia Type II - metabolism | Cardiovascular Agents - therapeutic use | Antioxidants - therapeutic use | Animals | Anticholesteremic Agents - therapeutic use | Antioxidants - adverse effects | Cardiovascular Agents - adverse effects | Probucol - history | Hyperlipoproteinemia Type II - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
by Ratziu, Vlad and Zelber-Sagi, Shira
Clinics in Liver Disease, ISSN 1089-3261, 11/2009, Volume 13, Issue 4, pp. 667 - 688
Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of... 
Sartans | Ursodesoxycholic acid | Fibrosis | Orlistat | Glitazones | Non-alcoholic steatohepatitis | Hepatoprotectants | Steatosis | VITAMIN-E | II RECEPTOR ANTAGONIST | FATTY LIVER-DISEASE | NECROSIS-FACTOR-ALPHA | STELLATE CELL ACTIVATION | WEIGHT-LOSS DIETS | RENIN-ANGIOTENSIN SYSTEM | LOW-CARBOHYDRATE-DIET | INSULIN-RESISTANCE | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | Betaine - therapeutic use | Tocopherols - therapeutic use | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Fatty Liver - prevention & control | Probucol - therapeutic use | Clinical Trials as Topic | Anti-Obesity Agents - therapeutic use | Cholagogues and Choleretics - therapeutic use | Fatty Liver - drug therapy | Lactones - therapeutic use | Pentoxifylline - therapeutic use | Ursodeoxycholic Acid - therapeutic use | Lipotropic Agents - therapeutic use | Antioxidants - therapeutic use | Thiazolidinediones - therapeutic use | Free Radical Scavengers - therapeutic use
Journal Article
Details down arrow
6. Full Text Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: The Intracoronary stenting and angiographic results: Test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) Trial
by Massberg, Steffen and Byrne, Robert A and Kastrati, Adnan and Schulz, Stefanie and Pache, Jürgen and Hausleiter, Jörg and Ibrahim, Tareq and Fusaro, Massimiliano and Ott, Ilka and Schömig, Albert and Laugwitz, Karl-Ludwig and Mehilli, Julinda and Intracoronary Stenting Angiographi and Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators
Circulation, ISSN 0009-7322, 08/2011, Volume 124, Issue 5, pp. 624 - 632
Background-Durable polymer coatings have been implicated in mid-and long-term adverse events after drug-eluting stent implantation. A polymer-free dual-drug... 
Zotarolimus | Probucol | Randomized clinical trial | Sirolimus | Drug-eluting stents | SYSTEM | CARDIAC & CARDIOVASCULAR SYSTEMS | drug-eluting stents | NON-INFERIORITY TRIAL | randomized clinical trial | RANDOMIZED-TRIAL | DRUG-RELEASE | LESIONS | probucol | ENDOTHELIALIZATION | RESPONSES | zotarolimus | REDUCTION | sirolimus | RESTENOSIS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | DURABLE POLYMER | Myocardial Infarction - mortality | Angioplasty, Balloon, Coronary - instrumentation | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Probucol - therapeutic use | Male | Angioplasty, Balloon, Coronary - statistics & numerical data | Prosthesis Design | Drug-Eluting Stents - adverse effects | Drug-Eluting Stents - statistics & numerical data | Female | Polymers - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Angioplasty, Balloon, Coronary - methods | Treatment Outcome | Coronary Artery Disease - mortality | Coronary Angiography | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Coronary Artery Disease - therapy | Polymers - chemistry | Aged | Usage | Care and treatment | Dosage and administration | Research | Comparative analysis | Coronary heart disease | Immunosuppressive agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Nanoassembly of Probucol Enables Novel Therapeutic Efficacy in the Suppression of Lung Metastasis of Breast Cancer
by Zhang, Zhiwen and Cao, Haiqiang and Jiang, Shijun and Liu, Zeying and He, Xinyu and Yu, Haijun and Li, Yaping
Small, ISSN 1613-6810, 11/2014, Volume 10, Issue 22, pp. 4735 - 4745
Metastasis is one of the major obstacles hindering the success of cancer therapy. The directed nanoassembly of probucol results in the “DNP” system, which... 
drug delivery | biomedical applications | nanoassembly | probucol | Drug delivery | Probucol | Biomedical applications | Nanoassembly | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | DRUG-DELIVERY | MATERIALS SCIENCE, MULTIDISCIPLINARY | NANOMEDICINE | TUMOR | RATS | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | CHEMISTRY, MULTIDISCIPLINARY | BIOAVAILABILITY | INTESTINAL LYMPHATIC TRANSPORT | MATRIX METALLOPROTEINASES | INHIBITION | COMPLEX NANOPARTICLES | ORAL DELIVERY | Microscopy, Electron, Transmission | Humans | Probucol - therapeutic use | Rats | Breast Neoplasms - drug therapy | Tissue Distribution | Animals | Lung Neoplasms - secondary | Breast Neoplasms - pathology | Female | Mice | Probucol - chemistry | Nanotechnology | Probucol - pharmacokinetics | Drugs | Drug delivery systems | Analysis | Breast cancer | Metastasis | Health aspects | Polyols | Vehicles | Medical research | Rodents | Self assembly | Lungs | Breast | In vitro testing | Nanostructure | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis: A Randomized Controlled Trial
by Tardif, Jean-Claude and Grégoire, Jean and L’Allier, Philippe L and Ibrahim, Reda and Lespérance, Jacques and Heinonen, Therese M and Kouz, Simon and Berry, Colin and Basser, Russell and Lavoie, Marc-André and Guertin, Marie-Claude and Rodés-Cabau, Josep and Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators, for the and ERASE Investigators and Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators
JAMA, ISSN 0098-7484, 04/2007, Volume 297, Issue 15, pp. 1675 - 1682
CONTEXT High-density lipoprotein (HDL) cholesterol is an inverse predictor of coronary atherosclerotic disease. Preliminary data have suggested that HDL... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | ANGIOPLASTY | PROBUCOL | REVERSE CHOLESTEROL TRANSPORT | INTERVENTION TRIAL | INTRAVASCULAR ULTRASOUND | ENDOTHELIAL FUNCTION | PROGRESSION | LESIONS | ARTERY-DISEASE | Cardiovascular Agents - administration & dosage | Phosphatidylcholines | Cholesterol, HDL - administration & dosage | Humans | Middle Aged | Ultrasonography, Interventional | Male | Coronary Artery Disease - drug therapy | Cholesterol, HDL - therapeutic use | Cardiovascular Agents - therapeutic use | Coronary Angiography | Coronary Artery Disease - diagnostic imaging | Myocardial Infarction | Apolipoprotein A-I | Angina, Unstable | Female | Aged | Infusions, Intravenous | Dosage and administration | Drug therapy | Cholesterol, HDL | Atherosclerosis | Clinical trials | Cardiovascular disease | Coronary vessels | Medical treatment | Cholesterol | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish
by Fang, Longhou and Green, Simone R and Baek, Ji Sun and Lee, Sang-Hak and Ellett, Felix and Deer, Elena and Lieschke, Graham J and Witztum, Joseph L and Tsimikas, Sotirios and Miller, Yury I
Journal of Clinical Investigation, ISSN 0021-9738, 12/2011, Volume 121, Issue 12, pp. 4861 - 4869
Oxidative modification of LDL is an early pathological event in the development of atherosclerosis. Oxidation events such as malondialdehyde (MDA) formation... 
ATHEROSCLEROTIC LESIONS | ANTIBODIES | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNIZATION | PROTEIN | CHOLESTEROL | LDL | MACROPHAGES | LOW-DENSITY-LIPOPROTEIN | OXIDATION-SPECIFIC EPITOPES | PROGRESSION | Recombinant Fusion Proteins - immunology | Temperature | Blood Vessels - metabolism | Humans | Recombinant Fusion Proteins - therapeutic use | Probucol - therapeutic use | Antibodies, Monoclonal - therapeutic use | Green Fluorescent Proteins - genetics | Cholesterol, Dietary - pharmacokinetics | Hypercholesterolemia - drug therapy | Epitopes - immunology | Single-Chain Antibodies - genetics | Hydrazines - analysis | Single-Chain Antibodies - therapeutic use | Zebrafish Proteins - immunology | Hypercholesterolemia - therapy | Lipoproteins, LDL - metabolism | Porphobilinogen - analogs & derivatives | Drug Evaluation, Preclinical | Antibodies, Monoclonal - immunology | Genes, Reporter | Disease Models, Animal | Malondialdehyde - metabolism | Macrophages - ultrastructure | Green Fluorescent Proteins - analysis | Immunoglobulin Fab Fragments - genetics | Oxidation-Reduction | Animals, Genetically Modified | Zebrafish Proteins - metabolism | Malondialdehyde - analogs & derivatives | Porphobilinogen - analysis | Microscopy, Confocal - methods | Zebrafish - growth & development | Zebrafish - genetics | Antibodies, Monoclonal - genetics | Macrophages - metabolism | Animals | Anticholesteremic Agents - therapeutic use | Microscopy, Fluorescence - methods | Malondialdehyde - immunology | Veins - metabolism | Zebrafish - metabolism | Recombinant Fusion Proteins - genetics | Hypercholesterolemia - metabolism | Lipoproteins, LDL - immunology | Single-Chain Antibodies - immunology | Care and treatment | Hypercholesterolemia | Zebra fish | Lipids | Diagnosis | Properties | Diseases | Technical Advance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin–Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial
by Jin, Sang-Man and Han, Kyung Ah and Yu, Jae Myung and Sohn, Tae Seo and Choi, Sung Hee and Chung, Choon Hee and Park, Ie Byung and Rhee, Eun Jung and Baik, Sei Hyun and Park, Tae Sun and Lee, In-Kyu and Ko, Seung-Hyun and Hwang, You-Cheol and Cha, Bong Soo and Lee, Hyoung Woo and Nam, Moon-Suk and Lee, Moon-Kyu
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 10/2016, Volume 36, Issue 10, pp. 2108 - 2114
OBJECTIVE—To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting... 
Angiotensin II Type 1 Receptor Blockers - adverse effects | Dyslipidemias - complications | Diabetic Nephropathies - etiology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Probucol - therapeutic use | Diabetic Nephropathies - drug therapy | Male | Probucol - adverse effects | Diabetic Nephropathies - diagnosis | Albuminuria - physiopathology | Dyslipidemias - blood | Diabetic Nephropathies - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Albuminuria - diagnosis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Cholesterol, LDL - blood | Female | Diabetes Mellitus, Type 2 - complications | Dyslipidemias - diagnosis | Kidney - physiopathology | Republic of Korea | Dyslipidemias - drug therapy | Kidney - drug effects | Tertiary Care Centers | Albuminuria - etiology | Double-Blind Method | Treatment Outcome | Biomarkers - blood | Anticholesteremic Agents - adverse effects | Diabetes Mellitus, Type 2 - diagnosis | Anticholesteremic Agents - therapeutic use | Albuminuria - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Renin-Angiotensin System - drug effects | Aged | Lipoproteins, LDL - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection
by Kume, Aiko and Herbas, Maria Shirley and Shichiri, Mototada and Ishida, Noriko and Suzuki, Hiroshi
Parasitology Research, ISSN 0932-0113, 1/2016, Volume 115, Issue 1, pp. 69 - 75
The current preventions of malaria are protection against mosquito bites and taking chemoprophylactic anti-malarial drugs. However, drug therapies are usually... 
Medical Microbiology | Biomedicine | Immunology | Microbiology | Malaria | Probucol | Alpha-tocopherol | Anti-hyperlipidemia drugs | Plasmodium yoelii | SELECTIVE UPTAKE | BERBERINE | CHOLESTEROL ABSORPTION | INTESTINAL-ABSORPTION | TRANSFER PROTEIN | PLASMA-LEVELS | IN-VIVO | DENSITY-LIPOPROTEIN | CASSETTE TRANSPORTER A1 | VITAMIN-E TRANSPORT | PARASITOLOGY | Antimalarials - adverse effects | Specific Pathogen-Free Organisms | Cholestyramine Resin - therapeutic use | Mice, Inbred C57BL | Probucol - therapeutic use | alpha-Tocopherol - blood | Male | Vitamin E Deficiency - chemically induced | Antimalarials - therapeutic use | Parasitemia - drug therapy | Mice, Knockout | Malaria - prevention & control | Animals | Anticholesteremic Agents - therapeutic use | Plasmodium yoelii - drug effects | Vitamin E Deficiency - complications | Female | Ezetimibe - therapeutic use | Mice | Berberine - therapeutic use | Malaria - drug therapy | Drug interactions | Dosage and administration | Observations | Alpha tocopherol | Health aspects | Risk factors | Antilipemic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease
by Poirier, Judes and Miron, Justin and Picard, Cynthia and Gormley, Patrick and Théroux, Louise and Breitner, John and Dea, Doris
Neurobiology of Aging, ISSN 0197-4580, 2014, Volume 35, Issue 2, pp. S3 - S10
Abstract The discovery that the apolipoprotein E ( apoE ) ε4 allele is genetically linked to both sporadic and familial late-onset Alzheimer's disease (AD)... 
Neurology | Internal Medicine | Apolipoprotein E | Lipids | Genetics | Probucol | Alzheimer's disease | Cholesterol | Statins | AMYLOID BETA-PROTEIN | E GENOTYPE | PROBUCOL TREATMENT | ESTER TRANSFER PROTEIN | AD MOUSE MODELS | E KNOCKOUT MICE | NEUROSCIENCES | GERIATRICS & GERONTOLOGY | IDENTIFIES VARIANTS | E-DEFICIENT MICE | GENOME-WIDE ASSOCIATION | TRANSGENIC MICE | Alzheimer Disease - etiology | Apolipoprotein E4 - genetics | Peptide Fragments - cerebrospinal fluid | Apolipoproteins E - deficiency | Genetic Association Studies | Humans | Probucol - therapeutic use | Alzheimer Disease - drug therapy | Homeostasis | Lipid Metabolism | Male | tau Proteins - cerebrospinal fluid | Apolipoproteins E - metabolism | Brain - metabolism | Probucol - pharmacology | Anticholesteremic Agents - therapeutic use | Apolipoproteins E - cerebrospinal fluid | Alleles | Alzheimer Disease - metabolism | Amyloid beta-Peptides - cerebrospinal fluid | Female | Phosphorylation - drug effects | Anticholesteremic Agents - pharmacology | Development and progression | Drug therapy | Apolipoproteins | Anticholesteremic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention
by Wang, Y and Shi, Y and Xu, XS and Ge, WK and Yang, S and Lu, CZ
MEDICINE, ISSN 0025-7974, 06/2019, Volume 98, Issue 25, p. e16049
Objective: This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease... 
contrast-induced acute kidney injury | MEDICINE, GENERAL & INTERNAL | EFFICACY | INDUCED NEPHROPATHY | DISEASE | preventive | probucol | Prospective Studies | Double-Blind Method | Acute Kidney Injury - drug therapy | Humans | Middle Aged | Probucol - therapeutic use | Logistic Models | Male | Coronary Angiography - adverse effects | Antioxidants - pharmacology | Probucol - pharmacology | Antioxidants - therapeutic use | Contrast Media - adverse effects | Percutaneous Coronary Intervention - methods | China | Coronary Disease - diagnostic imaging | Contrast Media - therapeutic use | Female | Aged | Coronary Disease - surgery | Percutaneous Coronary Intervention - adverse effects | Acute Kidney Injury - etiology | Prevention | Complications and side effects | Care and treatment | Usage | Angioplasty | Causes of | Probucol | Dosage and administration | Coronary heart disease | Acute renal failure | Methods | Contrast media
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial
by Tardif, Jean-Claude, Dr and McMurray, John JV, MD and Klug, Eric, MD and Small, Robert, PhD and Schumi, Jennifer, PhD and Choi, Jasmine, MSc and Cooper, Jim and Scott, Robert, MD and Lewis, Eldrin F, MD and L'Allier, Philippe L, MD and Pfeffer, Marc A, MD and ARISE Trial Investigators and Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators
Lancet, The, ISSN 0140-6736, 2008, Volume 371, Issue 9626, pp. 1761 - 1768
Summary Background Oxidative stress and inflammation are involved in the pathophysiology of atherosclerosis. Our aim was to assess the effects of the... 
Internal Medicine | SELECTIVE-INHIBITION | FEMORAL ATHEROSCLEROSIS | MEDICINE, GENERAL & INTERNAL | OXIDATIVE STRESS | B TYPE-I | NOD MICE | CLINICAL-TRIAL | PROBUCOL | ANTIOXIDANT | ROSIGLITAZONE | EXPRESSION | Cardiovascular Diseases - etiology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetes Mellitus, Type 2 - prevention & control | Probucol - therapeutic use | Male | Probucol - adverse effects | Acute Coronary Syndrome - drug therapy | Antioxidants - therapeutic use | Probucol - analogs & derivatives | Acute Coronary Syndrome - complications | Endpoint Determination | Cardiovascular Diseases - mortality | Adult | Antioxidants - adverse effects | Female | Aged | Antioxidants | Oxidative stress | Usage | Patient outcomes | Atherosclerosis | Physiological aspects | Development and progression | Health aspects | Heart attack | Clinical trials | Heart attacks | Kinases | Acute coronary syndromes | Blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights